Werewolf Profits Beat, Yet Stock Plunges 29%

Werewolf Therapeutics (HOWL) reported fiscal 2026 Q2 earnings on July 31, 2026. The company posted a GAAP EPS of $0.08, beating analyst estimates by $0.40, while revenue reached $21 million, driven entirely by collaboration revenue from the JZP898 program sale.

Revenue

The total revenue of Werewolf increased by 0.0% to $21 million in 2026 Q2, up from $0 in 2025 Q2.

Earnings/Net Income

Werewolf returned to profitability with EPS of $0.08 in 2026 Q2, reversing from a loss of $0.40 per share in 2025 Q2 (120.0% positive change). Meanwhile, the company achieved a remarkable turnaround with net income of $3.67 million in 2026 Q2, representing a 120.4% positive swing from the net loss of $-17.98 million in 2025 Q2. Record Low. The strong EPS performance reflects successful asset monetization, marking a significant operational improvement compared to prior periods.

Price Action

The stock price of Werewolf has plummeted 29.38% during the latest trading day, has plummeted 17.31% during the most recent full trading week, and has edged down 1.89% month-to-date.

Post-Earnings Price Action Review

Despite reporting a return to profitability and a significant beat on earnings per share, Werewolf Therapeutics experienced a sharp negative market reaction. The stock plummeted 29.38% on the day of the earnings release, indicating that investors may be prioritizing the company’s ongoing strategic uncertainty and cash burn concerns over the immediate financial improvement. This downward momentum extended into the following week, with the share price falling an additional 17.31% over the most recent full trading week. Month-to-date, the stock has declined by 1.89%, reflecting broader skepticism regarding the company's ability to sustain growth without the recent one-time collaboration revenue from the JZP898 program sale. The disconnect between positive fundamentals and negative price action highlights the market's cautious stance on the firm's future operational trajectory and strategic alternatives process.

CEO Commentary

Daniel J. Hicklin, Ph.D., President and Chief Executive Officer, highlighted the completion of the asset purchase agreement for the JZP898 program with Jazz Pharmaceuticals and the full repayment of debt to K2 HealthVentures. These transactions, which included a $21.0 million payment, enabled the Company to explore strategic alternatives for its INDUKINE and INDUCER platforms. Mr. Hicklin indicated that the second half of 2026 will bring updates on the strategic alternatives process, assisted by Piper Sandler, alongside clinical data updates for WTX-124 and WTX-330. His tone reflects a pragmatic focus on capitalizing on recent asset sales to fund future strategic evaluation and clinical progression amidst shifting operational priorities.

Guidance

The Company projects that its current cash position of $22.0 million, as of June 30, 2026, will be sufficient to fund operations into the second quarter of 2027. Management expects to provide additional updates regarding the strategic alternatives process being conducted with financial advisor Piper Sandler during the second half of the year. Furthermore, the Company anticipates releasing data updates on its clinical trials for WTX-124 and WTX-330 within this timeframe. However, the Company explicitly states it does not have a defined timeline for the exploration of strategic alternatives and cannot confirm that the process will result in any specific transaction or agreement enhancing stockholder value.

Additional News

Werewolf Therapeutics recently announced a significant workforce reduction, cutting 64% of its staff in February 2026 to align with strategic shifts. The company also engaged Piper Sandler & Co. as an exclusive financial advisor to assist in evaluating a full range of strategic alternatives for its pipeline. This move follows the sale of the JZP898 program to Jazz Pharmaceuticals, which provided crucial capital. These actions underscore a pivot toward optimizing resources and exploring partnerships or sales to maximize shareholder value amidst a challenging operational environment.